000			03062cam a2200349 a 4500
003			EG-GiCUC
005			20250223032527.0
008			200224s2019 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.03.Ph.D.2019.Ma.I
100	0		_aMariam Maged Fathy Mohamed Elhaddad
245	1	0	_aImpact of TP53 mutation and angiogenesis on the response to induction therapy in newly diagnosed Egyptian pediatric acute lymphoblastic leukemia patients / _cMariam Maged Fathy M. Elhaddad ; Supervised Mahmoud Hassan Fawzy Elguibaly , Alaa Mohamed Elhaddad , Basma Mostafa Elgamal
246	1	5	_aوتولد الاوعية الدموية على الاستجابة للعلاج الاستهلالى فى الاطفال المصريين مرضى سرطان الدم الليمفاوى الحاد TP53 تاثير طفرة
260			_aCairo : _bMariam Maged Fathy Mohamed Elhaddad , _c2019
300			_a133 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
520			_aBackground: Acute lymphoblastic leukemia (ALL) is a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites. It is the most common leukemia in children. In ALL, TP53 mutations have been poorly investigated, mainly in children. Tumorsuppressor pathways such as TP53 function in part by reducing the angiogenic potential of transformed cells. Limiting angiogenesis by TP53 occurs through the dual action of inhibiting proangiogenic signals and increasing production of angiostatic factors. To our knowledge this issue was poorly investigated in Egypt, Middle East and in international publications. Objective: In this study we investigated the impact of TP53 gene mutation and angiogenesis on the induction of remission in Egyptian children newly diagnosed of having ALL. Patients and methods: This study included 40 de novo Egyptian pediatric ALL patients referred from the pediatric oncology outpatient clinics in NCI-Cairo University in the period between May 2015 to June 2016. Bone marrow aspiration (BMA) and trephine biopsy (BMB) were obtained from all patients at diagnosis. Immunohistochemistry (IHC) will be carried out using anti CD- 34 monoclonal antibodies to study microvascular density (MVD) as marker of angiogenesis and BM aspirates were cultured, harvested and prepared for fluorescent in situ hybridization (FISH) to study TP53. All patients received total 15 induction therapy and were assessed at day 42 (end of phase 2 induction)
530			_aIssued also as CD
653		4	_aAngiogenesis
653		4	_aMVD
653		4	_aTP53
700	0		_aAlaa Mohamed Elhaddad , _eSupervisor
700	0		_aBasma Mostafa Elgamal , _eSupervisor
700	0		_aMahmoud Hassan Fawzy Elguibaly , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAsmaa _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c76776 _d76776